The US Food and Drug Administration’s Qualified Infectious Disease Product (QIDP) designation program is growing slowly, but it is growing, as 2019 has seen a rash of new designations in new indications for QIDP status for Iterum Therapeutics PLC’s penem antibiotic sulopenem and Polyphor Ltd.’s Pseudomonas-targeting murepavadin, as well as a QIDP for a third candidate from Spero Therapeutics Inc..
The QIDP designation count for Iterum’s sulopenem reached seven, thanks to new designations for community-acquired bacterial pneumonia (CABP), acute bacterial prostatitis,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?